BIM
VYGR icon

Bogle Investment Management’s Voyager Therapeutics VYGR Stock Holding History

Bogle Investment Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-25,660
Closed -$482K – 355
2018
Q1 		$482K Buy
+25,660
New +$555K 0.04% 267

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Bogle Investment Management's VYGR Position: Q2 2018 in Review

Bogle Investment Management sold out of Voyager Therapeutics (VYGR) in Q2 2018, closing a stake of 25,660 shares — an estimated $482K sold.

Bogle Investment Management first reported a position in VYGR in Q1 2018 and held it in 1 quarter. The position peaked at $482K in Q1 2018. 125 funds tracked by Wall St. Rank hold VYGR as of Q2 2018.

  • Bogle Investment Management reported no remaining Voyager Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Bogle Investment Management sold 25,660 Voyager Therapeutics shares in Q2 2018, an estimated $482K.
  • Bogle Investment Management first reported a position in Voyager Therapeutics in Q1 2018 and held it in 1 quarter.
  • Bogle Investment Management's Voyager Therapeutics position peaked at $482K in Q1 2018.
  • 125 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2018.

Based on Bogle Investment Management's 13F filing for Q2 2018, filed 13 Aug 2018.